Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 4/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.77 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.77 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.77 |
| ▸ | ALK known ✓ | Q9UM73 | 1/20 | 0.77 |
| ▸ | CDK2 | P24941 | 12/20 | 0.98 |
| ▸ | CCNK | O75909 | 9/20 | 0.98 |
| ▸ | CDK12 | Q9NYV4 | 9/20 | 0.98 |
| ▸ | CDK9 | P50750 | 8/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.98 |
| ▸ | CDK1 | P06493 | 8/20 | 0.98 |
| ▸ | CDK7 | P50613 | 6/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.98 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.98 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.98 |
| ▸ | CCND1 | P24385 | 4/20 | 0.98 |
| ▸ | CCNH | P51946 | 4/20 | 0.98 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927174 | 0.99 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL13001905 | 0.99 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL29644968 | 0.99 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL13001902 | 0.99 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL3690866 | 0.95 | CDK2 (0.92) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL20383014 | 0.90 | CDK2 (0.83) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL19705772 | 0.90 | CDK2 (0.83) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL23683123 | 0.90 | CDK5 (0.82) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL17628573 | 0.90 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL13001898 | 0.90 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399602-A1 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-24 | — | — | US | claimed |
| CN-112041428-A | Method for differentiating human pluripotent stem cell lines in suspension culture | 新加坡科技研究局 | 2020-12-04 | — | — | CN | claimed |
| EP-3740566-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | Agency for Science, Technology and Research (SG) | 2020-11-25 | — | — | EP | claimed |
| WO-2019143292-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-25 | — | — | WO | claimed |
| US-20250188420-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-06-12 | — | — | US | disclosed |
| EP-4516894-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-03-05 | — | — | EP | disclosed |
| CN-119072542-A | Maturation-promoting agent having ALK 5-inhibiting activity and CDK 8/19-inhibiting activity | 千纸鹤治疗公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-112041428-B | Method for differentiating human pluripotent stem cell lines in suspension culture | 新加坡科技研究局 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023233339-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR THERAPEUTICS AG (CH) | 2023-12-07 | — | — | WO | disclosed |
| EP-4271798-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR Therapeutics AG (CH) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023210578-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | オリヅルセラピューティクス株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-20230092398-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR THERAPEUTICS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| WO-2022144632-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR THERAPEUTICS AG (CH) | 2022-07-07 | — | — | WO | disclosed |
| US-20220204934-A1 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | CRISPR THERAPEUTICS AG (CH) | 2022-06-30 | — | — | US | disclosed |
| US-20200399602-A1 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-24 | — | — | US | disclosed |
| CN-112041428-A | Method for differentiating human pluripotent stem cell lines in suspension culture | 新加坡科技研究局 | 2020-12-04 | — | — | CN | disclosed |
| EP-3740566-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | Agency for Science, Technology and Research (SG) | 2020-11-25 | — | — | EP | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2019143292-A1 | METHOD FOR DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELL LINES IN SUSPENSION CULTURE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | CDK4 6/4885CDK6 154/4885CACNA1B 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.